CLL Coverage from Every Angle

Arnon P. Kater, MD, PhD, on Treatment Advantages With Ibrutinib Plus Venetoclax for Older Patients With CLL

Posted: Wednesday, July 7, 2021

Arnon P. Kater, MD, PhD, of the University of Amsterdam, discusses the clinical implications of findings from the phase III GLOW study, which suggests that fixed-duration ibrutinib and venetoclax, for previously untreated older patients with chronic lymphocytic leukemia, improves progression-free survival, and offers depth and duration of remission, as well as extended time to next treatment.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.